Perfect patches for patients 3 November 2015 Summary Medherant - PowerPoint PPT Presentation

Perfect patches for patients 3 November 2015

Summary • Medherant is developing a new class of drug delivery patch that can provide a variety of USPs to products • Formed as a spin-out from the world leading polymer chemistry group at University of Warwick • Exclusive, worldwide technology license from Bostik • Medherant patches have broad applications and offer multiple benefits • Wide range of chemical compatibility • High loading of both high and low-potency drugs • Good adhesion and clean removal • Clear and flexible – attractive and easy to wear • Simple, low-cost manufacture • We are seeking co-development partners and investors to support development of our own products

Patches • Benefits of patches • Dose control • Avoidance of GI damage (whether to patient or drug) • Convenience • Steady release • Current limitations • Available for very few drugs • Difficult to formulate for low-potency drugs • Poor patient experience in some cases • Simple matrix patches limited by low loading, loss of adhesion • Partially overcome by reservoir type patches, but these are cumbersome and complex to manufacture

Medherant patches • Single layer, drug in adhesive matrix • Simple and cheap to manufacture • Higher loadings than current patches or gels • Compatible with a wide range of drug types • High range of MWts and hydrophobicities • Steady rate of drug release • Can tailor rate with addition of excipients • Excellent adhesion, even at high drug loading • Clear, thin, flexible and attractive • No residues after removal

Drug compatibility Prolonged high dose rate for both low potency (l) and high potency drugs (r)

Drug release: Medherant vs Market leaders Enhanced long-term drug delivery

Adhesion Peel adhesion test • Strong adhesion even at high drug loadings • Combined with flexibility gives good adhesion to joints, curved surfaces • Easily removable • No tearing • No residues

Products available for licensing Ibuprofen patch Methyl Salicylate patch • • First ever Ibuprofen patch High drug loading (10-30% w/v) • • Long lasting High drug loading (10-30% w/v) • • Adhesion not hampered by Tailored delivery profile high drug load • 1hr – 12hr • • Enhanced comfort Colourless and transparent • • Choice of backing materials Highly adhesive yet easy to remove

Conclusion • Medherant has an excellent platform technology for the development of a wide range of drug delivery patch products with significant USP’s • We are seeking: • Partners for the development of our Methyl Salicylate patch and for the first ever Ibuprofen patch • Investors for our Series A round in Spring 2016 • We offer: • Rapid, low- cost feasibility studies to explore NCE’s that may benefit from transdermal delivery due to problems with GI toxicity or first pass metabolism or for life cycle management

Thank you Nigel Davis, CEO +44 7711 983344 www.medherant.co.uk